ESMO Gynaecological Cancers Congress 2026: Key Scientific Advances from the Oral Sessions

The European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress 2026, held in Copenhagen, Denmark, from June 17 to 19, 2026, brought together more than 1,270 participants from over 70 countries and featured more than 40 international speakers, 171 scientific abstracts, six Proffered Papers, and ten Rapid Oral presentations. The scientific program reflected the continued evolution of gynecologic oncology, with particular emphasis on immunotherapy, antibody–drug conjugates, and biomarker-guided treatment strategies.Selected oral presentations evaluated novel antibody–drug conjugates targeting FRα, HER2, B7-H4, and nectin-4, as well as emerging immunotherapy approaches in endometrial and cervical cancers. Additional studies explored biomarkers and treatment-selection tools, including KELIM and circulating immune signatures, with the aim of refining patient selection and informing therapeutic decision-making.This meeting summary reviews the principal findings from selected oral presentations, placing them within their clinical context and discussing their potential implications for future research and the management of gynecologic malignancies.